Novel Neuroprotective Agents to Treat Neonatal Hypoxic-Ischemic Encephalopathy: Inter-Alpha Inhibitor Proteins.

Abstract

Perinatal hypoxia-ischemia (HI) is a major cause of brain injury and mortality in neonates. Hypoxic-ischemic encephalopathy (HIE) predisposes infants to long-term cognitive deficits that influence their quality of life and place a large burden on society. The only approved treatment to protect the brain after HI is therapeutic hypothermia, which has limited effectiveness, a narrow therapeutic time window, and is not considered safe for treatment of premature infants. Alternative or adjunctive therapies are needed to improve outcomes of full-term and premature infants after exposure to HI. Inter-alpha inhibitor proteins (IAIPs) are immunomodulatory molecules that are proposed to limit the progression of neonatal inflammatory conditions, such as sepsis. Inflammation exacerbates neonatal HIE and suggests that IAIPs could attenuate HI-related brain injury and improve cognitive outcomes associated with HIE. Recent studies have shown that intraperitoneal treatment with IAIPs can decrease neuronal and non-neuronal cell death, attenuate glial responses and leukocyte invasion, and provide long-term behavioral benefits in neonatal rat models of HI-related brain injury. The present review summarizes these findings and outlines the remaining experimental analyses necessary to determine the clinical applicability of this promising neuroprotective treatment for neonatal HI-related brain injury.

• Authors: Liam M Koehn, Xiaodi Chen, Aric F Logsdon, Yow-Pin Lim, Barbara S Stonestreet
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 21 Issue 23 (Dec 02 2020) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 33276548 (Publication Type: Journal Article, Review)

Chemical References

• Alpha-Globulins
• Neuroprotective Agents
• inter-alpha-inhibitor

Topics

• Alpha-Globulins (chemistry, genetics, metabolism)
• Animals
• Brain Injuries (diagnosis, drug therapy, etiology, metabolism)
• Disease Management
• Disease Susceptibility
• Humans
• Hypoxia-Ischemia, Brain (diagnosis, drug therapy, etiology, metabolism)
• Infant, Newborn
• Neurons (metabolism)
• Neuroprotection
• Neuroprotective Agents (pharmacology, therapeutic use)
• Structure-Activity Relationship